Source: Health Products Regulatory Authority (ZA) Revision Year: 2022 Publisher: iPharma (Pty) Ltd, 124 Elevation Avenue, Randjesfontein, Midrand, 1683, South Africa
Comarest, 50 microgram/ml, Ophthalmic Solution.
| Pharmaceutical Form |
|---|
|
Ophthalmic solution. Sterile, colourless or pale yellow, clear solution. |
Each millilitre contains latanoprost 50 microgram.
One drop contains approximately 1,5 microgram latanoprost.
Excipients with known effect:
Each millilitre contains benzalkonium chloride 0,02% m/v as preservative.
Sodium dihydrogen phosphate monohydrate (E339i) 7,70 mg/ml.
Disodium phosphate anhydrous (E339ii) 1,55 mg/ml.
For full list of excipients, see section 6.1.
| Active Ingredient |
|---|
|
The active substance latanoprost, a prostaglandin F2α analogue, is a selective prostanoid FP receptor agonist which reduces the intraocular pressure (IOP) by increasing the outflow of aqueous humour. Reduction of the IOP in man starts about three to four hours after administration and maximum effect is reached after eight to twelve hours. |
| List of Excipients |
|---|
|
Benzalkonium chloride |
It is supplied as a 3 ml solution in a 5 ml clear low density polyethylene (LDPE) bottle with a clear LDPE dropper tip and a high density polyethylene (HDPE) screw cap.
Each bottle contains 3 ml eye drop solution corresponding to approximately 80 drops.
iPharma (Pty) Ltd, 124 Elevation Avenue, Randjesfontein, Midrand, 1683, South Africa
49/15.4/0154
12 July 2022
| Drug | Countries | |
|---|---|---|
| COMAREST | South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.